Brief: Clearmind Announces Positive Safety Findings For Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation In Part A Of Its FDA-Regulated Clinical Trial
30/07/2026 13:37
BRIEF-Clearmind Announces Positive Safety Findings For Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation In Part A Of Its FDA-Regulated Clinical Trial July 30 (Reuters) - Clearmind Medicine Inc CMND.O:
CLEARMIND ANNOUNCES POSITIVE SAFETY FINDINGS FOR CMND 100, DEMONSTRATING CONSISTENT TOLERABILITY THROUGHOUT FULL DOSE ESCALATION IN PART A OF ITS FDA-REGULATED CLINICAL TRIAL
CLEARMIND MEDICINE - ALL 24 PARTICIPANTS SUCCESSFULLY COMPLETE TREATMENT IN PART A OF CMND-100 TRIAL
CLEARMIND MEDICINE - NO SERIOUS ADVERSE EVENTS OBSERVED IN PART A OF CMND-100 TRIAL
CLEARMIND MEDICINE - STUDY ACHIEVES PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY FOR CMND-100
Source text: ID:nGNXb54NbC
Further company coverage: CMND.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearmind Medicine
See all newsBrief: Clearmind Advances Dialogue With U.S. Federal Government On Psychedelic Therapies, Submitting Recommendations To FDA
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM